Posted by Michael Wonder on 31 Jan 2025
Vertex announces Casgevy reimbursement agreement for the treatment of sickle cell disease in England
31 January 2025 - Agreement means eligible sickle cell disease patients in England now have access to Casgevy.
Vertex Pharmaceuticals announced today a reimbursement agreement with NHS England for eligible sickle cell disease patients to access the CRISPR/Cas9 gene-edited therapy, Casgevy (exagamglogene autotemcel).
